Introduction: The objective of this analysis was to describe in real-life settings the clinical
INTRODUCTION
Skin and soft tissue infections (SSTIs) are the consequence of a microbial invasion of the layers of the skin and underlying soft tissues [1] .
Complicated SSTIs (cSSTIs) represent more severe cases that involve deeper soft tissues and often require surgical treatment (e.g., infected ulcers, burns or major abscesses) [2] . Moreover, associated comorbidities and microbial factors, particularly drug resistance, make the treatment of cSSTI more challenging [3] .
Staphylococcus aureus is the main causative pathogen of cSSTIs [3] . Further, methicillinresistant S. aureus (MRSA) complicates their treatment. The percentages of MRSA isolates reported in Europe range from 0.7% (Sweden) to 53.9% (Romania) [4] . Prolonged hospital stay, economic burden and significant morbidity are associated with cSSTI due to MRSA [5] .
The glycopeptide vancomycin has been widely used for the treatment of MRSA infections, and its overuse has resulted in the emergence of vancomycin-intermediate and vancomycin-resistant S. aureus [6] . As a consequence, the increase of the minimum inhibitory concentrations (MICs) of vancomycin for MRSA is now a major challenge [7, 8] . Increased relapse rates have been reported for MRSA infections with a high vancomycin MIC [9] .
Early therapy with anti-MRSA agents in cSSTI reduces in-hospital mortality, shortens length of hospital stay and decreases treatment cost [10, 11] . Therefore, the initial antibiotic treatment of cSSTI is frequently empirical before identification of the causative pathogen. Empirical coverage of both methicillin-susceptible S. aureus (MSSA) and MRSA infections is important, because failure of initial antibiotic therapy in cSSTI is significantly associated with worse clinical and economic outcomes [12] .
Daptomycin, a cyclic lipopeptide, displays rapid bactericidal activity against a wide range of Gram-positive pathogens including pathogens resistant to methicillin and vancomycin [13] . Daptomycin is approved for the treatment of cSSTI (4 mg/kg/day), rightsided infective endocarditis due to S. aureus and bacteremia associated with cSSTI or right-sided infective endocarditis (6 mg/kg/day) [14] . In two pivotal trials, the clinical success rate in patients with cSSTI was 83.4% [15] . Of interest, daptomycin required a shorter duration of treatment than comparator antibiotics chosen by the study investigators [15] . 
Statistical Analysis
The safety population included all eligible patients with at least one safety assessment and the efficacy population included all eligible patients for whom clinical outcome was assessed.
Owing to the nature of the trial, inferential analyses were not performed and no formal statistical methodology other than simple descriptive statistics was used. Continuous variables were summarized as arithmetic mean, standard deviation, median and range; categorical variables were summarized by absolute and relative frequencies.
Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS

Patient Demographic and Clinical
Characteristics
Of Table 1 . The majority of patients were male (63.8%, n = 1230) and had a median age of 63.0 years (range 1-103). The most frequent underlying diseases were cardiovascular disease (58.1%, n = 1119) and diabetes mellitus (40.7%, n = 784). The most frequent cSSTIs were surgical site infections (SSIs; 34.9%, n = 673), wound infections (20.2%, n = 389), and diabetic foot infections (19.9%, n = 383).
Microbiology
Culture results were available for 82.0% (1580/ 1927) of patients; culture was positive for 82.1%
(1297/1580) of them. The most frequent primary pathogens isolated from patients with cSSTI were S. aureus (51.9%, n = 673) and to a lesser degree coagulase-negative Staphylococcus (CoNS) (17.5%, n = 227), including
Staphylococcus epidermidis (10.9%, n = 141; Table 2 ). MRSA was reported in 31.5%
(n = 408) of patients, whereas MSSA was isolated in 16.4% (n = 213) of patients with cSSTI. , n = 154), cephalosporins (7.0%, n = 134), or glycopeptides (6.6%, n = 127).
Concomitant antibiotics were given more frequently to hospitalized patients (61.8%, n = 1190) than to outpatients (3.3%, n = 63).
The most common concomitant antibiotics were carbapenems (22.9%, n = 442) and fluoroquinolones (15.6%, n = 301).
Daptomycin Prescribing Patterns
Daptomycin was prescribed as a first-line therapy in 34.2% (n = 659) of patients and as second-line therapy in 58.4% (n = 1126) of patients. The commonly prescribed doses of daptomycin in patients with cSSTI were 4 mg/kg/day (38.9%, n = 750) and 6 mg/kg/day (35.2%, n = 678). Of the 408 patients with MRSA infection, 32.1%
(n = 131 were treated with 4 mg/kg/day and 30.6% (n = 125) with 6 mg/kg/day. However, among the 62 patients with MSSA infection, the most common dose of daptomycin was 6 mg/kg/day (59.7%), followed by 4 mg/kg/day (25.8%).
Higher doses ([6 mg/kg/day and B10 mg/kg/day) were received by 11.1% (n = 214) of patients and 0.2% (n = 3) of patients received doses [10 mg/kg/day.
The total median duration of therapy in patients with cSSTI was 11 days with a range of 1-210 days [10.0 days for outpatients (range 
Clinical Outcomes
Clinical success rates were high for all doses. The overall clinical success rate (cured or improved) was 84.7% (n = 1632); 6.1% (n = 118) patients had treatment failure, and 9.2% (n = 177) patients were non-evaluable.
High clinical success rates were observed in all subtypes of cSSTI. The clinical success rates for cSSTI subtypes were highest for diabetic ulcer infections (91.6%) and superficial incision SSIs (88.1%; Fig. 1 ). Overall, clinical success rates by primary pathogen were comparable as detailed in Fig. 2 .
The median time to improvement in patients with cSSTI was 4 days in patients receiving a daptomycin dose of 4 mg/kg/day (range 1-37) or 6 mg/kg/day (range 1-41).
Safety
Overall, 10.5% (n = 203) of patients reported AEs including 2.4% (n = 46) with AEs possibly related to daptomycin (Table 3) . Daptomycin was discontinued due to an AE for 2.4% (n = 47) of patients.
Increased blood creatine phosphokinase (CPK) was reported for 1.3% (n = 26) of patients and multi-organ failure for 1.2% (n = 24). SAEs were reported for 5.9% (n = 114) of patients, of whom 0.6% (n = 12) with SAEs possibly related to daptomycin. A majority of patients received either 4 mg/kg/day (38.9%), the approved dose of daptomycin for cSSTI without bacteremia, or 6 mg/kg/day (35.2%), which is approved for cSSTI with bacteremia. Doses [6 mg/kg/day were received by 11.1% of patients. These high doses could reflect treatment of patients with serious or deep-seated cSSTIs (e.g., diabetic foot infection, major abscess).
Moreover, recent guidelines recommend the use of high doses of daptomycin (from 8 to 10 mg/kg/day) in patients with moderate-tosevere or severe MRSA SSTIs associated with ischemia [18] .
The high clinical success rate (84.7%) observed in the present EU-CORE study is in line with the results observed in the CORE study [19] . These results are also consistent with previously reported randomized clinical trials which assessed the efficacy of daptomycin in patients with cSSTI [15, 20] . In the two pivotal studies of Arbeit et al. [15] , the clinical success rate was 83.4% (372/446). In a randomized Phase IIIb trial, Konychev et al. [20] observed a clinical success of 89.0% (65/73) in elderly patients (C65 years) receiving daptomycin as first-line treatment for cSSTI. Quist et al. [11] reported a clinical success of 91.4% (53/58) in a randomized clinical trial in patients with firstline treatment of daptomycin. In the metaanalysis of Wang et al. [21] that included six randomized controlled trials, the overall clinical success in patients with cSSTI was 85.5% (630/ 737). Therefore, these results further support the use of daptomycin as a first-line treatment option for cSSTI.
Our results confirmed in real-world settings a comparable high effectiveness across infections caused by various pathogens, in particular MRSA. These results support the use of daptomycin as empiric treatment for cSSTI.
Indeed, S. aureus is the most frequent pathogen causing cSSTIs and it is advantageous to start treatment with antibiotics that are effective against both MSSA and MRSA in settings with high MRSA rates. Early treatment of cSSTI caused by MRSA was associated with lower in-hospital mortality rates, shorter length of hospital stay and lower total costs [10] .
The current analysis displayed high clinical success rates in different types of cSSTI including diabetic foot infection, which is a serious, difficult-to-treat infection [18] . These results support previous results from Joseph et al. who showed that success in patients with diabetic foot infection treated with daptomycin was higher in patients who had surgery and when initial therapy was 
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